Within the secondary analysis, the significantly less conservative but clinically meaningful criterion of steady response (described for a fifty% or more reduction in MADRS from baseline for 2 months) was used. In the patients who attained stable reaction, twenty five.eight% during the esketamine group and fifty seven.6% inside the placebo group re